Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.

Molecular cancer therapeutics - 1 Jan 2015

Fink Lauren S, Beatty Alexander, Devarajan Karthik, Peri Suraj, Peterson Jeffrey R

Abstract excerpt

Triple-negative breast cancers (TNBC), negative for estrogen receptor, progesterone receptor, and ERBB2 amplification, are resistant to standard targeted therapies and exhibit a poor prognosis. Furthermore, they are highly heterogeneous with respect to genomic alterations, and common therapeutic targets are lacking though substantial evidence implicates dysregulated kinase signaling. Recently, six subtypes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Protein Kinase Inhibitors

Share to Protein Kinases

Share to PTEN Phosphohydrolase

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25344583
DOI: 10.1158/1535-7163.MCT-14-0529
PMCID: PMC4297247

Genes

ERBB2
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.PMID 25344583Read ↗

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Semantic proximity Read ↗

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.Semantic proximity Read ↗

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous diseaseSemantic proximity Read ↗

Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast CancerSemantic proximity Read ↗

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.Semantic proximity Read ↗

Subtype and pathway specific responses to anticancer compounds in breast cancerSemantic proximity Read ↗

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read ↗

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.